a Independent Researcher , Vallejo , CA , USA.
Drug Dev Ind Pharm. 2018 Nov;44(11):1868-1870. doi: 10.1080/03639045.2018.1504962. Epub 2018 Sep 5.
Substandard, falsified, and counterfeit medications are a concern for the industry and for the public's health. Data collection and research on these illegitimate drugs must continue to be a priority and common recommendations must be implemented immediately. The health of the public continues to be at risk, and as such global consensus and collaboration must be swift. Process improvements and policy decisions can support expert recommendations while technology and research continue to drive home change. Addressing counterfeit and substandard drugs is cost effective, feasible, and the right thing to do.
劣药、假药和假冒伪劣药品是业界和公众健康关注的问题。必须继续将这些非法药物的数据收集和研究作为优先事项，并立即实施共同建议。公众的健康仍然存在风险，因此必须迅速达成全球共识并开展合作。流程改进和政策决策可以支持专家建议，而技术和研究则继续推动变革。解决假冒伪劣药品问题具有成本效益，切实可行，也是正确的做法。
